Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New app aims to ease the burden on dementia caregivers

NCT ID NCT06418971

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a mobile app called CarePair that helps family caregivers of people with dementia find services and support. About 80 caregivers will use the app for six weeks to see if it is easy to use and helps reduce stress and depression. The goal is to see if the app is a helpful tool for caregivers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CarePair mobile application
What this could lead to
If it works, this could provide a practical tool to help family caregivers of people with dementia feel less stressed and more supported.
What could go wrong
This is a small, early-stage study testing feasibility, not effectiveness. The app may not reduce caregiver burden or depression as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion: * Currently a primary caregiver of a community-dwelling PwD * Provides at least 10 hours of care per week * ≥18 years of age * Fluent in English * Both the caregiver and care-recipient reside in and/or can easily access one of the following cities/areas: New York City, New York (NY); Long Island, NY; Westchester County, NY; Seattle, Washington (WA); Los Angeles, California (CA) * Provides at least 10 hours of care per week * Has provided care for at least 6 months * Able to use the internet and has internet access * Owns and can operate a smartphone * Able and willing to provide their informed consent to participate for the six-week study duration * Does not self-report any cognitive impairments Exclusion: * Not currently the primary caregiver of a community-dwelling person with dementia * Care-recipient lives in residential care (e.g., assisted living, skilled nursing facility) * ≤18 years of age * Not fluent in English * The caregiver and/or care-recipient resides outside of and/or cannot easily access any of the following cities: New York City (NY); Long Island (NY); Westchester County (NY); Seattle (WA); Los Angeles (CA) * Provides less than 10 hours of care per week * Has provided care for less than 6 months * Unable to use the internet or does not have internet access * Does not own and/or cannot operate a smartphone * Unable or unwilling to provide informed consent to participate for the six-week study duration * Self-reports having a cognitive impairment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Caregiver burden are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Caregiver Burden dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Southern California

    RECRUITING

    Los Angeles, California, 90089, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.